As­traZeneca reshuf­fles Chi­na lead­er­ship, sets up bio­phar­ma group to mir­ror glob­al struc­ture

As­traZeneca’s Chi­na group has reshuf­fled its lead­er­ship and set up a new bio­phar­ma group fol­low­ing the de­par­ture of its gen­er­al man­ag­er in on­col­o­gy, ac­cord­ing to re­ports in Chi­nese me­dia.

Justin Chin, a nine-year vet­er­an of the drug­mak­er who most re­cent­ly led the on­col­o­gy busi­ness in Chi­na, is re­turn­ing to Sin­ga­pore for fam­i­ly rea­sons, sev­er­al out­lets re­port­ed, cit­ing an in­ter­nal an­nounce­ment. Chi­na gen­er­al man­ag­er Michael Lai will fill his role, while Alex Lin — who’s al­ready in charge of res­pi­ra­to­ry, bi­o­log­ics as well as Hong Kong and Macau — will lead the new­ly-es­tab­lished bio­phar­ma unit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER